Abstract
Protein-splicing inteins are widespread in nature and have found many applications in protein research and engineering. The mechanism of protein splicing typically requires a nucleophilic amino acid residue at both position 1 (first residue of intein) and position +1 (first residue after intein), however it was not clear whether or how the three different nucleophilic residues (Cys, Ser, and Thr) would work differently at these two positions. To use intein in a target protein of interest, one needs to choose an intein insertion site to have a nucleophilic residue at position +1, therefore it is desirable to know what nucleophilic residue(s) are preferred by different inteins. In this study we began with a statistical analysis of known inteins, which showed an unequal distribution of the three nucleophilic residues at positions 1 and +1, and then subjected six different mini-inteins to site-directed mutagenesis to systematically test the functionality of the three nucleophilic residues at the two positions. At position 1, most natural inteins had Cys and none had Thr. When the Cys at position 1 of the six inteins was mutated to Ser and Thr, the splicing activity was abolished in all except one case. At position +1, Cys and Ser were nearly equally abundant in natural inteins, and they were found to be functionally interchangeable in the six inteins of this study. When the two positions were studied as 1/+1 combination, the Cys/Ser combination was abundant in natural inteins, whereas the Ser/Cys combination was conspicuously absent. Similarly, all of the six inteins of this study spliced with the Cys/Ser combination, whereas none spliced with the Ser/Cys combination. These findings have interesting implications on the mechanism of splicing and the selection of intein insertion sites, and they also produced two rare mini-inteins that could splice with Thr at position +1.
Keywords: intein, protein splicing, mutagenesis, IMPACT protein, nucleophilic residue, Intein sequence analysis and alterations, DNA sequencing, PCR, DNAMAN, GE Healthcare, IPTG, DNA, SDS-PAGE, MIT, thermophilic Archaea inteinsintein, protein splicing, mutagenesis, IMPACT protein, nucleophilic residue, Intein sequence analysis and alterations, DNA sequencing, PCR, DNAMAN, GE Healthcare, IPTG, DNA, SDS-PAGE, MIT, thermophilic Archaea inteins
Protein & Peptide Letters
Title: Alternative Nucleophilic Residues in Intein Catalysis of Protein Splicing
Volume: 18 Issue: 12
Author(s): Xingmei Qi, Jin Wang, Qing Meng and Xiang-Qin Liu
Affiliation:
Keywords: intein, protein splicing, mutagenesis, IMPACT protein, nucleophilic residue, Intein sequence analysis and alterations, DNA sequencing, PCR, DNAMAN, GE Healthcare, IPTG, DNA, SDS-PAGE, MIT, thermophilic Archaea inteinsintein, protein splicing, mutagenesis, IMPACT protein, nucleophilic residue, Intein sequence analysis and alterations, DNA sequencing, PCR, DNAMAN, GE Healthcare, IPTG, DNA, SDS-PAGE, MIT, thermophilic Archaea inteins
Abstract: Protein-splicing inteins are widespread in nature and have found many applications in protein research and engineering. The mechanism of protein splicing typically requires a nucleophilic amino acid residue at both position 1 (first residue of intein) and position +1 (first residue after intein), however it was not clear whether or how the three different nucleophilic residues (Cys, Ser, and Thr) would work differently at these two positions. To use intein in a target protein of interest, one needs to choose an intein insertion site to have a nucleophilic residue at position +1, therefore it is desirable to know what nucleophilic residue(s) are preferred by different inteins. In this study we began with a statistical analysis of known inteins, which showed an unequal distribution of the three nucleophilic residues at positions 1 and +1, and then subjected six different mini-inteins to site-directed mutagenesis to systematically test the functionality of the three nucleophilic residues at the two positions. At position 1, most natural inteins had Cys and none had Thr. When the Cys at position 1 of the six inteins was mutated to Ser and Thr, the splicing activity was abolished in all except one case. At position +1, Cys and Ser were nearly equally abundant in natural inteins, and they were found to be functionally interchangeable in the six inteins of this study. When the two positions were studied as 1/+1 combination, the Cys/Ser combination was abundant in natural inteins, whereas the Ser/Cys combination was conspicuously absent. Similarly, all of the six inteins of this study spliced with the Cys/Ser combination, whereas none spliced with the Ser/Cys combination. These findings have interesting implications on the mechanism of splicing and the selection of intein insertion sites, and they also produced two rare mini-inteins that could splice with Thr at position +1.
Export Options
About this article
Cite this article as:
Qi Xingmei, Wang Jin, Meng Qing and Liu Xiang-Qin, Alternative Nucleophilic Residues in Intein Catalysis of Protein Splicing, Protein & Peptide Letters 2011; 18 (12) . https://dx.doi.org/10.2174/092986611797642760
DOI https://dx.doi.org/10.2174/092986611797642760 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Hot Topic: Potential Targets for the Rational Design of Antiparasitic Drugs (Executive Editor: Mahmoud H. el Kouni) ]
Current Pharmaceutical Design Enhanced Crystallizability by Protein Engineering Approaches: A General Overview
Protein & Peptide Letters Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mycobacterium tuberculosis Treatment Modalities and Recent Insights
Current Drug Delivery Structural Genomics and Drug Discovery for Infectious Diseases
Infectious Disorders - Drug Targets Review of the Biological Activity of Maslinic Acid
Current Drug Targets Anti-Tubercular and Anti-Inflammatory Activities of Azetidin-2-One Derivatives and Their Effects on the Activity of Phospholipase A2
Medicinal Chemistry Genomics and the Prospects for the Discovery of New Targets for Antibacterial and Antifungal Agents
Current Pharmaceutical Design Tuberculostatic Drugs Targeting Infections of the Central Nervous System
Anti-Infective Agents The Roles of Antimicrobial Peptides in Innate Host Defense
Current Pharmaceutical Design Synthesis, Characterizations and Microbial Studies of Novel Mannich Products Using Multicomponent Reactions
Current Bioactive Compounds Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review
Cardiovascular & Hematological Disorders-Drug Targets Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
Current Pharmaceutical Design Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Synthesis, Anticonvulsant and Antimicrobial Activities of Some New [1-(2-Naphthyl)-2-(pyrazol-1-yl)ethanone]oxime Ethers
Medicinal Chemistry Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Carbohydrate Mimics and Lectins: A Source of New Drugs and Therapeutic Opportunities
Mini-Reviews in Medicinal Chemistry Phylogenetic and Functional Classification of ATP-Binding Cassette (ABC) Systems
Current Protein & Peptide Science Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology